Show Summary Details
Page of

Essential pharmacology of antithrombotic agents 

Essential pharmacology of antithrombotic agents
Essential pharmacology of antithrombotic agents

Thomas Cuisset

, Stefan K. James

, Andrea Rubboli

, Lars H. Rasmussen

, Giancarlo Agnelli

, and Gregory Y. H. L Lip

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 December 2020

Aspirin is a relatively weak antiplatelet agent, which acts through the irreversible inhibition of the platelet enzyme cyclo-oxygenase-1. P2Y12-receptor inhibitors, including thienoyridinesclopidogrel, and prasugrel, and cyclopentyl-triazolo-pyrimidine ticagrelor are potent oral antiplatelet agents. Among parenteral anticoagulants subcutaneous low-molecular-weight heparin enoxaparin,fondaparinux, and intravenous bivalirudineach show a superior efficacy to safety relationship. Vitamin K-antagonists act by impairing the hepatic synthesis of coagulation factors II, V, VII, and IX, and are complex to manage. Newer non vitamin K-antagonists, direct oral anticoagulants inhibit single coagulation factors (thrombin, factor Xa), and have predictable anticoagulant effects with no need for routine laboratory monitoring.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.